Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
US technology stocks sold off sharply on Thursday, as a bruising slump in Microsoft sparked investor unease over how long it will take for mass AI investments to pay off. The tech-heavy Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results